Rigrodsky & Long, P.A. Announces Investigation Of BioClinica, Inc. (NASDAQ GM: BIOC) Buyout

  • Do you own shares of BioClinica, Inc. (NASDAQ GM: BIOC)?
  • Did you purchase any of your shares prior to January 30, 2013?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

If the answer to these questions is "yes," please contact the deal lawyers at Rigrodsky & Long, P.A. ("R & L") today to schedule a FREE consultation. Just call us, or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.

Contact R & L today to be sure your best interests are being protected.

R & L is a national law firm with decades of combined legal experience. R & L is investigating potential claims against the board of directors of BioClinica, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by JLL Partners for $7.25, or approximately $123 million.

Click here to read the full press release.

Rigrodsky & Long, P.A. Announces Investigation Of BioClinica, Inc. (NASDAQ GM: BIOC) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of BioClinica, Inc. (“BioClinica” or the “Company”) (NASDAQ GM: BIOC) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by JLL Partners, Inc. (“JLL”) in a transaction valued at approximately $123 million.

Under the terms of the proposal, public shareholders of BioClinica will receive $7.25 per share in cash for each share of BioClinica they own. 

The investigation concerns whether BioClinica’s board of directors failed to adequately shop the Company and obtain the best possible value for BioClinica’s shareholders before entering into an agreement with JLL.  According to Yahoo! Finance, at least one analyst has set a price target for BioClinica stock at $9.00.                          

If you own the common stock of BioClinica and purchased your shares before January 30, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530 toll free at (888) 969-4242, by e-mail to info@rigrodskylong.com.          

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

R & L, with offices in Delaware and New York, litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Learn more about R&L:  Visit Our WebsiteOur Firm  |  Our Practice Areas  |  FAQ's

Fill out the form below or call us toll-free at 888-969-4242, for a FREE no-obligation consultation.